The goal of this project is design of pain relief drugs (opioids), which should be active only in inflamed tissue and therefore have reduced side effects compared to conventional opioids. We managed to develop a candidate, which was synthesized by the ASCA GmbH in Berlin. The opioid is currently undergoing in-vivo and in-vitro experiments at the Charité Berlin.